PDUFA date for sBLA on NHL drug Zevalin is July 2.

Spectrum Pharmaceuticals will receive $9.5 million from two existing investors through a direct offering. It included some 170,000 shares at a price of $5.83 for a total of $10 million. The firm is currently preparing for its PDUFA date, scheduled for July 2, related to a label expansion for lymphoma drug Zevalin.

The drug is already approved to treat patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL), including those who have rituximab-refractory follicular NHL. It is under priority review as a consolidation therapy in patients with follicular B-cell non-Hodgkin’s lymphoma who achieve a response to first-line therapy.

Zevalin is being developed and commercialized by RIT Oncology, a joint venture set up between Spectrum and Cell Therapeutics in November 26, 2008, for this particular purpose. Since then, Cell Therapeutics has completely sold its 50% stake in RIT in favor of near-term cash to help with development and regulatory activities related to pixantrone, its lead candidate for NHL. Cell Therapeutics obtained $15 million when RIT was formed and $18 million when it sold its stake.

Now approval of Zevalin rests on Spectrum’s shoulders. “The addition of Zevalin as a consolidation therapy could represent a significant advancement and a changing treatment paradigm for patients with non-hodgkin’s lymphoma,” says Rajesh C. Shrotriya, Spectrum chairman, president, and CEO. “Patients achieving a complete remission after induction chemotherapy who received Zevalin consolidation achieved a median progression-free survival benefit of greater than 67 months, compared to 30.8 months in the control arm.” 

Previous articleCangene to Use Upfront’s Platform to Produce Antibodies from Plasma
Next articleMDRNA Revises Agreement with RiboTask for UNA Technology